and HG Pá lmer 3 SPROUTY2 (SPRY2) is an intracellular regulator of receptor tyrosine kinase signaling involved in cell growth, differentiation and tumorigenesis. Here, we show that SPRY2 is a target gene of the Wnt/b-catenin pathway that is abnormally activated in more than 90% of colon carcinomas. In human colon cancer cells, SPRY2 expression is induced by b-catenin in co-operation with the transcription factor FOXO3a instead of lymphoid enhancer factor/T-cell factor proteins. We found binding of b-catenin to the SPRY2 promoter at FOXO3a response elements. In vivo, cells marked by nuclear b-catenin and FOXO3a express SPRY2 in proliferative epithelial tissues, such as intestinal mucosa and epidermis. Consistently, inducible b-catenin deletion in mice reduced Spry2 expression in the small intestine. Moreover, SPRY2 protein expression correlated with nuclear b-catenin and FOXO3a colocalization in human colon carcinomas. Importantly, the amount of SPRY2 protein correlated with shorter overall survival of colon cancer patients. Our data reveal SPRY2 as a novel Wnt/b-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer.
INTRODUCTION
Colorectal cancer (CRC) is the second cause of death by cancer worldwide. 1 Constitutive activation of the Wnt/b-catenin pathway by mutations is an initiating event in more than 90% of human CRC. 2 In normal tissues without Wnt pathway activation, cytosolic b-catenin is recruited to a destruction complex that contains the scaffold Axin and Adenomatous polyposis coli proteins, casein kinase a/e and glycogen synthase kinase 3b. b-Catenin phosphorylation by these two kinases commits it towards degradation by the proteasome. When Wnt signaling is activated, the destruction complex is disassembled, and b-catenin is not phosphorylated, translocating to the cell nucleus where it binds the lymphoid enhancer factor/T-cell factor (lymphoid enhancer factor, LEF/human T-cell factor 1, TCF) family of transcription factors. b-Catenin/TCF complexes control the expression of many genes involved in cell proliferation and invasion, thus promoting tumor initiation and progression. 3 In addition, b-catenin has been shown to bind other transcription factors enhancing the expression of alternative sets of target genes and directing cell fate in tissue homeostasis, development and cancer. [4] [5] [6] [7] [8] One of these transcription factors is FOXO3a, that induces genes responsible for apoptosis, cell cycle arrest and response to oxidative stress. 9 Furthermore, FOXO3a and TCF/LEF factors compete for the binding of limited amounts of nuclear b-catenin as transcriptional co activator: while nuclear FOXO3a accumulation reduces b-catenin/TCF transcriptional activity, 10 b-catenin/FOXO3a complexes regulate genes involved in longevity and oxidative stress. 11 In addition, we recently described that nuclear b-catenin and FOXO3a co-operate to induce a complete set of genes involved in colon cancer metastasis. 8 In this context, we have now evaluated in detail SPROUTY2 (SPRY2) as a potential target gene of the Wnt/b-catenin pathway by enhancing FOXO3a transcriptional activity. Indeed, transcriptome and promoter analyses of mouse endothelium identified Spry2 as a direct FoxO target gene that mediates endothelial cell morphogenesis and vascular homeostasis.
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SPRY2 expression is downregulated in the breast, prostate, hepatocellular carcinoma and in B-cell diffuse lymphoma, suggesting a tumor suppressive role. [13] [14] [15] [16] [17] Contrarily, it is upregulated in melanoma cell lines concomitantly to N-RAS and B-RAF activating mutations. 18, 19 Data regarding colon cancer are contradictory. While it was reported that SPRY2 RNA levels are downregulated in some intestinal tumors, 13 we and others have reported an increased expression of SPRY2 in high-grade undifferentiated carcinomas as compared with normal intestinal mucosa in colon cancer patients. 20, 21 Furthermore, SPRY2 reduces the expression of the tumor suppressor E-cadherin responsible of retaining cell-to-cell contacts and inhibiting cell motility. Contrarily, SPRY2 knockdown diminishes cell invasion in human colon cancer cells. 20, 21 To help clarifying the role of SPRY2 in cancer, we decided to study the molecular mechanisms that control its expression and to analyze its potential value as prognostic marker in colon cancer, both relevant aspects that have not yet been explored in detail.
In this study, we reveal that SPRY2 expression is regulated by FOXO3a and b-catenin nuclear activity. Simultaneous accumulation of both factors in the nucleus induced an increase of SPRY2 RNA and protein in colon cancer cells. We detected b-catenin recruited to the SPRY2 gene at FOXO3a response elements by chromatin immunoprecipitation (ChIP) assays, confirming that it is a direct b-catenin target gene most probably through direct FOXO3a binding. Consistently, in normal mouse small intestine and human colon tissue, SPRY2 is expressed at the bottom of the crypts, the proliferative compartment where Wnt/b-catenin pathway is most active and FOXO3a is accumulated in the cell nucleus. Similarly, Spry2 is expressed in cells with nuclear b-catenin and FOXO3a proteins in the matrix of mouse hair follicles, a system whose growth is well established to be stimulated by Wnt ligands. 5, 22 In fact, Spry2 expression is reduced upon inducible intestinal deletion of b-catenin in mice, confirming that its expression is dependent on Wnt/b-catenin signaling activity in vivo. Furthermore, we found a direct correlation between SPRY2 protein expression and nuclear b-catenin and FOXO3a colocalization content in human colon carcinomas. Remarkably, SPRY2 expression correlates with shorter overall survival of colon cancer patients. Finally, we observed that simultaneous activation of b-catenin and FOXO3a enhances SPRY2 expression and epidermal growth factor receptor/extracellular signal-regulated kinase-AKT (EGFR/ERK-AKT).
Together, these data demonstrate that SPRY2 is a Wnt/b-catenin and FOXO3a target gene indicative of poor prognosis in colon cancer patients.
RESULTS
SPRY2 is a b-catenin and FOXO3a target gene in colon cancer cells To explore the possible regulation of SPRY2 expression by FOXO3a and b-catenin, we expressed a 4-hydroxytamoxifen (4OHT)-inducible, AKT-insensitive FOXO3A mutant (FOXO3A-ER) 23 and a doxycycline (DOX)-inducible, stabilized (non-degradable) b-catenin mutant (b-catenin S33Y ) in human DLD1 colon cancer cells (DLD1Fb). DLD1 cells were chosen for these experiments as they have low basal nuclear FOXO3a or b-catenin content and low b-catenin/TCF-driven transcriptional activity. 8 Both FOXO3a and b-catenin proteins accumulated in the nucleus upon corresponding inducible treatments (Figure 1a ). Exposure to 4OHT or DOX increased SPRY2 RNA amounts, and the combinatory treatment further induced its expression in DLD1Fb cells (Figure 1b) . The increase was also detected at protein level, and again it was higher when b-catenin and FOXO3a were simultaneously localized in the nucleus (Figure 1c ). SPRY2 phosphorylation is associated with electrophoretic mobility shift. Two bands are detected for SPRY2 protein corresponding to, serine residues phosphorylated form (upper band) and non-phosphorylated form (lower band). Phosphorylation of SPRY2 likely has a role in determining its stability and function status. [24] [25] [26] Regulation was specific as the expression of Sprouty family member SPRY1 did not increase following 4OHT and/or DOX addition. As expected, DOX induced the b-catenin/TCF target lymphoid enhancerbinding factor-1 (LEF1), whose expression was reduced by 4OHT-mediated FOXO3a induction probably owing to competition for b-catenin binding. 10 Besides, the expression of the cell cycle regulator p21 CIP1 , a reported FOXO3a target, was induced by 4OHT treatment. The inducible expression of an exogenous dominant-negative DNTCF4 in LS174T colon cancer cells repressed TCF/LEF-dependent transcription and the expression of target genes like C-MYC or AXIN2 27 but did not reduce SPRY2 expression, indicating that it is not a canonical TCF/LEF target gene ( Supplementary Figures 1a and b) .
We next examined whether b-catenin binds to the SPRY2 gene promoter at putative FOXO3a binding sites (DAF-16 binding element, DBEs) in DLD1Fb cells by ChIP assays. Among the nine putative DBEs that we identified across the sequence of the human SPRY2 coding and upstream promoter sequences, we only observed enrichment in b-catenin precipitation on those sites located next to the transcriptional start site (DBE2 and DBE3) (Figures 1d and e) . The maximum b-catenin enrichment upon DOX treatment was detected 1700 bp upstream of the SPRY2 start codon (DBE2) (Figures 1d and e) . b-Catenin was also enriched upon DOX and reduced upon 4OHT (FOXO3a) treatment at TCF binding sites on LEF1 promoter (Supplementary Figure 1c) . 10 Finally, we observed that exogenous nuclear b-catenin induced the activity of SPRY2 gene promoter region, extending from À 1826 to þ 221 bp, upon DOX treatment in DLD1Fb (Figures 1d and f) . This region contained the FOXO3a binding site DBE2, where b-catenin was most recruited in ChIP assays (Figures 1d and e) . SPRY2 expression in human colon epithelium and epidermis correlates with nuclear FOXO3a and b-catenin colocalization We next studied the expression of FOXO3a, b-catenin and SPRY2 proteins in human colon by immunofluorescence analyses. Whereas FOXO3a was equally accumulated in the nucleus of epithelial cells all across the human colon mucosa, b-catenin was nuclear only in some epithelial cells at the bottom of the crypts where the Wnt pathway is highly activated (Figures 2a-c) . Interestingly, SPRY2 protein was also enriched in epithelial cells at the bottom of colon crypts, and was found preferentially in the cytoplasm (Figures 2d and e) . In this same crypt area, epithelial cells express high levels of the b-catenin/TCF target CD44, high Ki67 and low cytokeratins, indicating high proliferation and poor differentiation ( Supplementary Figure 2a-c) . In summary, SPRY2 expression was concentrated at the bottom of the colon crypts, a region where cells present nuclear FOXO3a and b-catenin, Wnt/b-catenin pathway activation, 3 high proliferation rate and low differentiation (Supplementary Figure 2d) . SPRY2 is also expressed in stromal cells surrounding the intestinal epithelium.
We also analyzed FOXO3a, b-catenin and Spry2 expression in mouse hair follicles, in which growth is directly linked to Wnt pathway activation. 5, 22 b-Catenin and FOXO3a colocalized in the nucleus of epithelial cells at the matrix region of the growing anagen hair follicles ( Supplementary Figures 3a and b) . These epithelial cells are directly exposed to Wnt ligands secreted by the specialized stromal cells that populate the dermal papilla during the anagen hair growth phase 5, 22 (Supplementary Figure 4d) . Spry2 protein was detected just in the same hair matrix region, where FOXO3a and b-catenin simultaneously accumulated in the cell nucleus ( Supplementary Figures 3d and e) . The expression of CD44 and Lef1 Wnt/b-catenin target genes was high in this matrix region, where b-catenin was nuclear and Spry2 staining was positive ( Supplementary Figures 3d and 4a and b) . We observed that Spry2 expression coincided with that of keratin Ha1, which is a marker of early hair shaft differentiation (Supplementary Figure 4c) . Finally, we detected an enrichment of b-catenin bound to the DBE present at the proximal region of the Spry2 gene promoter, by performing ChIP assays with extracts of mouse skin that presented a majority of hair follicles at growing anagen phase ( Supplementary Figures 3c and 4e) .
In summary, these data indicate that Spry2 is expressed in cells that accumulate high levels of nuclear FOXO3a and b-catenin and in their immediate cell offspring in two highly proliferative tissues, human intestinal colon mucosa and mouse growing hair follicles (Figures 2g and 3g ).
Spry2 expression in mouse intestine requires b-catenin
We extended the study of Spry2 expression to the mouse intestine. Similarly to human tissue (Supplementary Figure 2c) , Spry2 was absent from the differentiated villi and accumulated in the proliferative area, colocalizing with Ki67 at the bottom of the intestinal crypts (Figure 3a ). However, Spry2 was predominantly detected at the cell membrane in mouse small intestinal tissue, whereas it was mostly cytoplasmic in human colonic intestine (Figures 2d and e, and 3a and c).
To determine whether b-catenin is essential for Spry2 expression in vivo, we used a mouse model of 4OHT-inducible ablation of b-catenin from epithelial cells of the intestine (villin-creERT2-bcatenin lox/lox ). (Figures 6a and b) . The induction of nuclear b-catenin and FOXO3a increased SPRY2 and EGFR expression and the concomitant activation of pAKT and pERK. Addition of EGF reduced the amount of its receptor EGFR by inducing its degradation, 29, 31 but simultaneously increased pEGFR, pAKT and pERK. Such activation was transient, decaying at later time points. When cells were pretreated with DOX þ 4OHT, EGF-induced activation of EGFR, AKT and ERK equally occurred, but signal decay was delayed and persisted longer time. In summary, cells with nuclear FOXO3a and b-catenin presented enhanced amplitude of response to EGF signal.
To explore the particular relevance of SPRY2 as a FOXO3a/ b-catenin target gene regulating EGFR, we knocked down its 
lox/lox mice promoted the decrease of pEGFR level (Figure 6e) . Therefore, the activity of b-catenin is required for the proper expression and/or activation of EGFR at the proliferative mouse crypts, where nuclear FOXO3a, b-catenin and Spry2 content is high.
DISCUSSION
The mammalian SPRY protein family consists of four members that bind to a variety of endogenous kinases, phosphatases and adapter proteins, which allow them to modulate the signaling of several growth factor tyrosine kinase receptors. 32 Tyrosine kinase receptor signaling is central in controlling the homeostasis of small intestine and colon epithelia. 33 In particular, SPRY2 modulates the EGFR signaling pathway. [29] [30] [31] Upon EGF stimulation of its receptor, the c-Cbl E3 ligase binds and ubiquitinates EGFR, targeting it to internalization and destruction by the endocytotic machinery. In this scenario, active SPRY2 competes with c-Cbl for the binding to EGFR, thus reducing receptor endocytosis and increasing the amplitude and duration of downstream Ras/mitogen-activated protein kinase pathway activation. [34] [35] [36] SPRY2 also interacts with the hepatocyte growth factorregulated tyrosine kinase substrate (Hrs) interfering with the trafficking of ligand-activated EGFR receptor from early to late endosomes, and thus increasing the signaling. 37 In contrast, in certain cellular contexts, SPRY proteins not only fail to enhance but may even inhibit tyrosine kinase receptors , indicating a complexity of SPRY function that warrants further detailed studies. 24, 26, 38, 39 Although such modulation of tyrosine kinase receptors signaling could have a relevant role in fundamental processes during development, adult tissue homeostasis and cancer initiation or progression, 33 no data about the regulation of SPRY2 expression was available up to now.
In this study, we show that nuclear colocalization of FOXO3a and b-catenin induces SPRY2 RNA and protein expression in colorectal carcinoma cells. We found that b-catenin interacts with two regions on the SPRY2 gene promoter where FOXO binding sequences are located, but which lack response elements for TCF/LEF or other transcription factors that interact with b-catenin. Besides, b-catenin enhances the activity of the proximal promoter region of SPRY2 gene. Altogether these data indicate that SPRY2 is a FOXO3a and b-catenin target gene induced through the recruitment of both factors to specific regulatory gene regions. It remains unknown whether FOXO3a and b-catenin would form part of the same regulatory protein complex on the SPRY2 gene promoter or would act independently.
In vivo, we have identified high SPRY2 expression in a subpopulation of Wnt/b-catenin-activated epithelial cells that also accumulate nuclear FOXO3a, either at the bottom of human intestinal crypts or in the matrix of mouse anagen hair follicles. SPRY2 expression is extended to the immediate offspring of proliferative cells activated by FOXO3a and b-catenin. These results together with the loss of Spry2 expression in the small intestine of b-catenin null mice, confirm SPRY2 as a b-catenin target gene.
Interestingly, the same cell populations at the bottom of the intestinal crypts and the matrix of the growing hair follicles expressing SPRY2 are highly activated by EGF ligands. 40 It is therefore possible that SPRY2, as a FOXO3a/b-catenin target gene, could be a key factor modulating the crosstalk between Wnt/ b-catenin and EGF signaling pathways in vivo. The cell populations located within these regions contain adult stem and progenitor cells, and both Wnt and EGF signals from the corresponding specialized niches are fundamental to sustain their distinct pluripotency and self-renewal capacities. 28, [41] [42] [43] Further studies that include the analysis of conditional tissue-specific Spry2 null mice should be performed to reveal its possible role in the physiology of adult stem cells and for the homeostasis of epithelial tissues. Indeed, mice carrying Spry2 null alleles die as a consequence of gastrointestinal abnormalities at postnatal day 21-28. 44 Although these data evidence that Spry2 is crucial for intestinal homeostasis, its exact role for intestinal stem cells physiology remains to be analyzed. Other processes dependent on the Wnt/ b-catenin pathway like limb, lung or kidney development are perturbed in vertebrates overexpressing the SPRY2 gene. 44 Altogether, these data suggest that the tight control of the precise amounts of SPRY2 by the Wnt/b-catenin pathway could be essential for an orderly execution of different biological processes during development or the homeostasis of various adult tissues.
Abnormal activation of the Wnt/b-catenin pathway by mutations, that promote nuclear accumulation of b-catenin, is an initiating event in more than 90% of colon cancer patients. Contrarily, FOXO3a is considered a tumor suppressor, as it can promote cell cycle arrest and apoptosis in cancer cells. Indeed, the combined knockdown of FOXO1, 3 and 4 in mice is responsible for tumor initiation. 12 However, we have recently demonstrated that the accumulation of high amounts of both FOXO3a and b-catenin in the nucleus of cancer cells imposes a high motile phenotype, promoting metastasis in mice and correlating with metastatic stages and shorter overall survival of colon cancer patients. 8 Similarly, we describe here that high levels of SPRY2 also correlate with shorter survival of colon cancer patients. Furthermore, supporting the idea of SPRY2 as an oncogene, we previously showed its capacity to increase the expression of ZEB1, an inducer of epithelial-to-mesenchymal transition, which promotes cell migration and invasion in colon cancer cells. 20 In this scenario, SPRY2 could have a role in the malignant phenotype of colon cancer cells as a b-catenin and FOXO3a target gene. Its activity could also modulate EGF signaling, which in fact is central in many colon carcinomas. Indeed, the use of anti-EGFR antibodies, such as Cetuximab has become one of the most important clinical strategies to treat K-RAS wild-type patients with advanced metastatic disease. Therefore, SPRY2 expression could be used to determine the response to Cetuximab as previously suggested. 45 Our data provide a better understanding of the consequences of Wnt/b-catenin pathway activation by including SPRY2 as a new target gene, which may modulate other signaling pathways like EGFR, relevant for tissue homeostasis and tumor progression. In fact, we observed a decrease in pEGFR content in mouse colon SPRY2
The limited effects of SPRY2 knockdown on EGFR signaling could indicate that FOXO3a and b-catenin increase the amplitude of EGFR signaling by regulating other factors. Indeed, we previously described that b-catenin and FOXO3a regulate the expression of multiple common target genes involved in cell signaling, proliferation and malignancy in colon cancer. Further investigations would be required to identify which are the FOXO3a/b-catenin target genes other than SPRY2 that determine such enhanced EGFR signaling. However, as in our experiments the expression of SPRY2 was only reduced by 58%, it SPRY2 is a b-catenin/FOXO3a target gene P Ordó ñ ez-Morán et al is also possible that a more efficient knockdown of SPRY2 expression may be necessary to detect an effect on the induction of EGFR signaling by FOXO3a and b-catenin. Furthermore, our data suggest that b-catenin and FOXO3a could execute part of their oncogenic activity by sustaining an enhanced EGFR-RAS-ERK/ AKT signaling. Such mechanism could determine tumor malignancy and progression, as the EGFR signaling drives central aspects of the cancer cell phenotype: hyperproliferation, enhanced survival, motility or migration. We found that SPRY2 is the only member of its family upregulated by b-catenin and FOXO3a. Such results are in line with previous evidences showing SPRY2 as the only member upregulated in colon cancer tumors compared with adjacent normal mucosa. 21 Altogether, these data highlight the relevance of SPRY2 in colon cancer malignancy. In summary, our results reveal SPRY2 as a new b-catenin and FOXO3a target gene that is expressed in Wnt-activated cells in normal and tumoral tissues and correlates with shorter overall survival of colon cancer patients. It should therefore be considered as a prognosis marker and a potential target to direct therapeutic intervention in the future.
MATERIALS AND METHODS
Cells, culture and treatments DLD1 human colon cancer cells were cultured in DMEM plus 10% fetal bovine serum (Invitrogen, Darmstadt, Germany). Cells were transfected with pcDNA-FOXO3A:ER 46 and neomycin-selected to obtain a clone of DLD1F cells. b-Catenin S33Y was introduced in DLDF (Dong Ling Di Fu) cells by infection with pSIN-TRE-flag-b-catenin S33Y -IRES-GFP lentivirus to generate the DLDFb cell line. Lentiviral particles were produced by transfecting 293T cells with lentiviral construct and packaging vectors (pPAX2 and pMD2.G, Addgene, Cambridge MA, USA). 8 Cells were treated as follows: 2.5 mg/ml Doxycycline (DOX, Sigma-Aldrich, St Louis, MO, USA) for 12 h before 50 nM 4-Hydroxytamoxifen (4OHT, Sigma-Aldrich) for 24 h. In experiments using EGF, cells were treated with DOX (same concentration) for 24 h before an additional 16 h incubation in serumfree medium in the presence of DOX and 4OHT (same concentrations), before the treatment with EGF (100 ng/ml) or vehicle.
SPRY2 knockdown was performed in DLD1Fb cells by infecting simultaneously with eight different lentivirus expressing short hairpin RNAs specific against human SPRY2 mRNA (Open BioSystems, Pittsburgh, PA, USA) and following previously described protocols.
8 DLD1Fb cells infected with lentivirus expressing control non-silencing short hairpin RNA were use as control. Quantitative reverse transcription-PCR Total cellular RNA was purified using RNeasy mini kit (Qiagen, Hilden, Germany). Values were normalized versus housekeeping gene succinate dehydrogenase complex subunit A. The reaction was performed in a LightCycler apparatus using the LightCycler-FastStart DNA MasterPLUS SYBR Green I Kit (Roche Diagnostics, Mannheim, Germany) or the High Capacity cDNA Reverse Transcription Kit, TaqMan SPRY2 Hs00183386_m1 and TaqMan Universal PCR Master Mix, no Amperase, (Applied Biosystems, Darmstadt, Germany). All experiments were performed by triplicate.
Western blotting
Whole-cell extracts were prepared by washing the monolayers twice in phosphate-buffered saline (PBS) and cell lysis by incubation in radioimmunoprecipitation assay buffer (50 mM Hepes pH 7.4, 150 mM NaCl, 1.5 mM MgCl2, 10% glycerol, 4 mM EDTA, 1% Triton X-100, 0.1% SDS, 1% deoxycholate) plus phosphatase and protease-inhibitor mixture (25 mM b-glycerophosphate, 1 mM Na3VO4, 10 mM NaF, 1 mM PMSF, 10 mg/ml leupeptin, 10 mg/ml aprotinin) for 15 min on ice followed by centrifugation at 13 000 r.p.m. for 10 min at 4 1C. Western blotting of cell lysates was performed by electrophoresis in SDS-polyacrylamide gel electrophoresis and protein transfer to Immobilon P membranes (Millipore, Darmstadt, Germany). The membranes were incubated with the appropriate primary and secondary horseradish peroxidase-conjugated antibodies, and the antibody binding was visualized using the ECL detection system (GE Healthcare, Chalfont St Giles, UK). Different exposure times of the films were used to ensure that bands were not saturated. Quantification of the films was performed by densitometry using ImageJ software (Bethesda, MD, USA).
ChIP and sequence analysis
ChIP was carried out as described previously 47 using b-catenin (BD Bioscience, Oxford, UK) or a species matched IgG control (Millipore) and LEF1 and SPRY2 promoter-specific primers. Previously described sequences of FOXO3a response elements (DBE) in the mouse Spry2 gene were identified in the homologous human SPRY2 gene using NTI software (Life Technologies, Beverly, MA, USA) and primers were designed accordingly for the ChIP analysis. Identification of putative response elements of other transcription factors able to interact with b-catenin on the SPRY2 gene sequence, was performed by TRANSFAC software (http://www.gene-regulation.com). We used a set of primers to analyze TCF/LEF binding sites in the human LEF1 gene. 48 Primer sequences were as follows: Spry2 A, forward 5 0 -GTTTCCAGTCCTTCAA GCAATC-3 0 , reverse 5 0 -AATTGGGAGTGGCTGTAACAAA-3 0 ; Spry2 B, forward
Luciferase assays Cells were transfected using the X-tremeGENE HP DNA reagent (Roche). In transient transfections, Firefly (Luc) and Renilla reniformis luciferase (Rluc) -villincreERT2 mice were used as a control. Immunohistochemical staining of murine small intestine for b-catenin (green) and the pEGFR (red) show a decrease in the expression of both proteins upon treatment. Nuclei were stained with Hoechst 33342 (blue). Asterisks indicate unspecific staining in the crypt lumen. Scale bar, 100 mm.
SPRY2 is a b-catenin/FOXO3a target gene P Ordó ñ ez-Morán et al activities were measured separately using the Dual Luciferase reagent kit (Promega) and a Centro XS 3 LB960 luminometer (Berthold, Bad Wildbad, Germany). Luc activity was normalized to the Rluc activity. The SPRY2 promoter activity was studied using the pGL-hSPRY2-Luc ( À 1826/ þ 221) construct. 49 To study b-catenin/TCF transcriptional activity, we used the TOP-Flash and FOP-Flash plasmids containing multimerized wild-type (5 0 -CCTTTGATC-3 0 ) or mutated (5 0 -CCTTTGGCC-3 0 ) TCF/LEF1 binding sites upstream of a minimal c-fos promoter driving luciferase gene expression 50 (a gift from Dr.H Clevers, Utrecht, The Netherlands).
Immunofluorescence and confocal microscopy Cultured cells were fixed in methanol at À 20 1C for 3 min and then washed four times in PBS. Cells were incubated with the primary antibodies diluted in PBS/3% BSA O/N at 4 1C. After four washes in PBS, the cells were incubated with secondary antibodies for 45 min at room temperature, washed three times in PBS and mounted using Prolong Gold antifade reagent (Molecular Probes-Invitrogen, Darmstadt, Germany). Conventional fixed and paraffin-embedded sections of human Stage III CRC tumors from a collection available in the Pathology Service of the Vall d'Hebron Hospital were prepared and immunolabelled as described elsewhere. 22 Briefly, antigens were retrieved by microwaving in 10 mM citrate buffer (pH 6.0) for 10 min and permeabilized with 0.2% Triton X-100 (Sigma-Aldrich). Nonspecific binding was blocked by incubating the sections in 10% BSA (SigmaAldrich) for 1 h. Cell imaging was performed on a Leica TCS SP5 DMI6000 microscope using argon ion (488 nm), HeNe (543 nm) and violet diode (405 nm) lasers. Images were acquired sequentially by direct register using Leica Confocal Software (LAS AF). Fluorescence images were analyzed and quantified with the MBF 'ImageJ for Microscopy' program (www.macbiophotonics.ca) using the criteria described earlier 8, 20 (Arqués, O. et al 
Isolation of intestinal crypts
Freshly isolated small intestines of villin-creERT2-b-catenin were incised along their length and villi were removed by scraping. The tissue was then incubated in PBS/EDTA pH ¼ 8 (2 mM) for 5 min at 4 1C. Gentle shaking removed remaining villi, and intestinal tissue was subsequently incubated in PBS/EDTA pH ¼ 8 for 30 min at 4 1C. Subsequently, cells were spun down, resuspended in PBS/FBS 5% and filtered through 70-mm mesh.
Antibodies
We used primary antibodies against b-catenin and EGFR (BD Transduction Laboratories, San Jose, CA, USA), SPRY2 (Abnova, Upstate, Darmstadt, Germany), C-MYC (9E10, Sigma-Aldrich), AXIN2 ab32197 (Abcam, Cambridge, UK) SPRY1 (Abcam), Pan-cytokeratin (Novocastra, Leica Microsystems GmbH Wetzlar, Germany), b-actin sc-1616, Lamin B sc-6216, AKT sc-1618, pERK sc-7383, ERK2 sc-154 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), CD44 (Ab4, Thermo Fisher Scientific, Waltham, MA, USA), CD44-6v (Bender MedSystems, Wien, Austria, ABIN 123916), LEF1 no. C18A7, pAKT no. 9271, pEGFR no. 3777 (Cell Signaling, Danvers, MA, USA), EGFR (phospho Y1068), p21 CIP (Millipore), Ki67 (MiB-1, Dako, Agilent Technologies, Santa Clara, CA, USA) and Ha1 (Progen, Heidelberg, Alemania). Secondary antibodies used: Alexa 488-conjugated goat antimouse and goat anti-rabbit IgG (H þ L) (Molecular Probes) and Alexa 546-conjugated goat anti-mouse, goat anti-rabbit and goat anti-rat IgG (H þ L) (Molecular Probes). Nuclei were stained using DAPI or Hoechst 33342 (Molecular Probes).
Statistical analysis
Significant difference between groups of values in reverse transcription-PCR (Figure 1b Difference between values in promoter luciferase assays were analyzed by a non-parametric t-test. We calculated correlation coefficients (r) with two-tailed non-parametric Spearman tests, which make no assumption about the distribution of the values to compare fluorescent signal values of different proteins in patientś tissue samples (Figure 6a ). We analyzed survival of patients by the Kaplan-Meier method and compared the curves using a Log-rank (Mantel-Cox) test assuming that hazard function is the same at all times (Figure 6b ). We considered significant P-values lower than 0.05.
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